Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AIM ImmunoTech Inc. (AIM)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.4700-0.1200 (-7.55%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5900
Open1.5700
Bid1.4800 x 800
Ask1.5300 x 1300
Day's Range1.4300 - 1.5800
52 Week Range1.1100 - 3.0600
Volume603,231
Avg. Volume340,834
Market Cap70.315M
Beta (5Y Monthly)-0.83
PE Ratio (TTM)N/A
EPS (TTM)-5.8730
Earnings DateAug 12, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.67
  • GlobeNewswire

    AIM ImmunoTech Provides Third Quarter 2021 Business Update

    OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. Third Quarter 2021 Financial Highlights: As of September 30, 2021, AIM had cash, cash equivalents and marketable securities of $53.7 million, compared to $54.4 million as of December 31, 2020. Research and development expenses for the three months ended September 30, 2021 were $2.0 million, compared to $

  • GlobeNewswire

    AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

    OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a planned Phase 2 study of the company’s drug Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The planned AMP-270 clinical trial of approximately 250 subjects will be a Phase 2, rand

  • GlobeNewswire

    AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy

    CHDR Table 1 CHDR Table 1 CHDR Table 2 CHDR Table 2 OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company’s belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19. AIM previously announced that the study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy was completed, and th

Advertisement
Advertisement